Tissue Phenomics Blog

5B_Her2-classified.jpg

Posts by Topic

see all

Topics:  tissue phenomics, clinical development, PK/PD, Definiens, Biomarker Datafication Services

How to Make Phase II Clinical Trial Investment Decisions Faster with Precise PK/PD Data

Aug 5, 2015 9:00:00 AM

At the end of a phase I clinical development project researchers need to justify further investment to advance their selected therapy into a Phase II trial. Thus, they need to know what the body’s physiology does to the drug and, most importantly, what the drug does to the body. In particular clinical researchers are looking for the following:

• Confirmation that the selected therapy reaches the tumor.
• Confirmation that the selected therapy affects the pathway as expected.

To get the relevant information needed for decision making, clinical researchers analyze tissue samples collected at several time points before and after dosing. With these tissue samples, the physiological response is identified by measuring biomarker expression at the various time points.

Read More

Topics:  Biomarker selection, Diagnostic Development, PK/PD, Companion Diagnostic Development, Biomarker Datafication Services

Biomarker Datafication Services for Clinical Development

Jun 8, 2015 9:00:00 AM

Achieve Valuable Data for Your Clinical Program Decision Making

Biomarker projects are critical to drug development programs and demonstrating the medical value of therapies. Success in these programs often comes down to having comprehensive data from tissue samples that can be used to make critical decisions on drug development advancements and assess the potential of a companion diagnostic for patient stratification.

To assist you in achieving the best and most comprehensive tissue data, Definiens is proud to announce our new Biomarker Datafication Services for clinical development.

Read More